The Prognostic Significance Of Inflammation Associated Blood Cell Markers In Metastatic Colorectal Cancer

Abstract

Objectives: The aim is to perform prognostic evaluation with overall survival (OS) and progression-free survival (PFS) in hematological parameter-based groups in patients with metastatic colorectal cancer (mCRC). Methods: In a single institution, 51 patients were retrospectively analyzed mCRC diagnosed between 2019 and 2022. Pretreatment hematological parameters of patients with mCRC receiving first-line chemotherapy in a single center were examined. The receiver operating characteristic curve was used to predict the tests. Median OS was calculated by the Kaplan-Meier method and compared with the log-rank test. Multivariate analyses were performed using a Cox regression model. Results: The median OS of the patients included in the study was 27 months (3-88 months) by statistical calculation; the median PFS was 19 months (2-84 months). The median could not be reached. Among the risk factors affecting OS, it was found effective to have a bone metastasis site and a pancreatic metastasis site (p values 0.003 and 0.027, respectively). In the analysis of the risk factors affecting PFS, bone and pancreatic metastases were found to be significant (p values 0.001 and 0.004, respectively). Patients receiving chemotherapy and anti-VEGF therapy have a significantly reduced risk of death of 0.06 times compared to those who do not receive chemotherapy, which indicates that OS is significantly longer in people receiving chemotherapy in question (p=0.020). It was observed that blood cell marker levels were not statistically significant in PFS and OS. Of the 51 patients included in the study, 30 of them were still being followed up, while 21 of them died. Conclusions: Chemotherapy plus anti-VEGF therapy is a treatment whose effectiveness has been determined in metastatic colorectal cancer. In the future, there is a need for more prospective and large patient group studies on this topic to measure the prognostic value of hematological parameters in metastatic colorectal cancer.